Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Completed × epratuzumab × Clear all

Phase

Phase 2 4 Phase NA 1 Phase 3 1 Phase 1/2 1

Status

Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 1

Interventions

Cyclophosphamide 121 Paclitaxel 112 Gemcitabine 110 Radiotherapy 106 Carboplatin 97 pembrolizumab 94 Cisplatin 91 Nivolumab 89 Docetaxel 82 Rituximab 73 Lenalidomide 68 Dexamethasone 62 Cytarabine 61 Bevacizumab 60 Etoposide 57 Filgrastim 55 Peripheral Blood Stem Cell Transplantation 54 Fluorouracil 54 Capecitabine 54 fludarabine phosphate 53 Temozolomide 52 Everolimus 52 Oxaliplatin 51 Prednisone 49 Irinotecan 48 Doxorubicin 47 Melphalan 45 Cetuximab 45 Erlotinib Hydrochloride 44 Bortezomib 43

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00421395 2021-08-16

Safety Study of NHL With 90Y-hLL2 IgG

Gilead Sciences

Phase 1/2 Completed

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡